Skip to main content

Table 1 Selected targeted agents for ovarian cancer evaluated in phase II studies*

From: Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs

Targeted molecular agents Primary molecular target FDA approved cancer sites Response rate in ovarian cancer Toxicities
Imatinib KIT, PDGF-R (TKI) GIST 0% ORR, 33% SD [20, 21] Fatigue, diarrhea, rash, nausea, cardiotoxicity, granulocytopenia
Trastuzumab HER-2 (mAB) Breast, gastroeosphageal 7.3% ORR [22] Fatigue, diarrhea, rash, cardiotoxicity, anemia, dyspnea, neutropenia
Pertuzumab HER-2 (TKI) Breast cancer 4.3% ORR, 6.8% SD [23] Diarrhea, neutropenia, nausea, LV dysfunction, VTE, vomiting, renal failure
Bevacizumab VEGF (mAB) Glioblastoma, NSCLC, mBreast, mCRC, mRCC 15-21% ORR, 25-52% SD [24, 25] Fatigue, diarrhea, anorexia, hypertension, gastrointestinal perforation, proteinuria, hemorrhage, congestive heart failure, arterial thromboembolism, wound healing problems
Gefitinib EGFR (TKI) NSCLC 0-4% ORR, 29-37% SD [2628] Diarrhea, rash, nausea, vomiting, mucositis, dyspnea
Erlotinib EGFR (TKI) NSCLC 6% ORR, 44% SD [29] Fatigue, diarrhea, rash, anorexia
Temsirolimus mTOR inhibitor RCC 9.3% ORR, 24.1% 6m PFS [30] Fatigue, diarrhea, rash, nausea, anorexia, stomatitis, anemia, hypertension, dyspnea
Vandetanib EGFR, TEGF, RET (TKI) Medullary thyroid cancer 0% ORR/SD [31] Diarrhea, rash, hypertension, proteinuria, asymptomatic, QT prolongation
Sorafenib VEGF, PDGF, c-Raf (TKI, Raf KI) RCC, hepatocellular carcinoma 3% ORR, 34% SD [32] Fatigue, diarrhea, rash, nausea, vomiting, anorexia, hypothyroidism, cardiotoxicity, hand–foot syndrome
Sunitinib VEGF, PDGF, KIT (TKI) RCC, GIST, pancreatic neuroendocrine tumor 3% ORR, 53% SD [33] Fatigue, diarrhea, nausea, vomiting, hypothyroidism, hypertension, cardiotoxicity
Pazopanib TKI VEGF, PDGFR (TKI) RCC, soft tissue sarcoma 31% ORR, 56% SD (Ca-125 response) [34] Fatigue, diarrhea, nausea, anorexia, hypertension, abdominal pain, arrhythmia, hepatotoxicity, hemorrhage
Lapatinib HER2, EGFR (TKI) Breast Cancer 0% ORR, 8 SD [35] QT prolongation, CYP3A4, GI toxicity
Olaparib PARP inbibitor n/a 24-41% ORR, 35%-59% SD (BRCA carriers) [36, 37] fatigue, somnolence, nausea, loss of appetite, thrombocytopenia
  1. *There are no FDA approved targeted agents in ovarian cancer.
  2. Abbreviations: TKI = tyrosine kinase inhibitor, mAB (monoclonal antbody), mTOR (mammalian target of rapamycin), PARP (Poly ADP-ribose polymerase), GIST (Gastrointestinal stromal tumor), NSCLC (non-small cell lung cancer), CRC (colorectal cancer), RCC (renal cell carcinoma), m (metastatic), ORR (overall response rate, REIST criteria if not specified), SD (stable disease).